BDX

$161.64

Post-MarketAs of Mar 17, 8:00 PM UTC

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

Recent News

StockStory
Mar 17, 2026

3 Reasons BDX is Risky and 1 Stock to Buy Instead

Over the last six months, BD’s shares have sunk to $160.20, producing a disappointing 14.6% loss while the S&P 500 was flat. This was partly due to its softer quarterly results and might have investors contemplating their next move.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 15, 2026

Assessing Becton Dickinson’s Valuation After Recent Share Weakness And Planned Business Separation

What recent returns say about Becton Dickinson (BDX) Becton Dickinson (BDX) has been under pressure, with the share price showing a 0.2% decline over the past day, about 4.6% over the past week, and roughly 9.4% over the past month. See our latest analysis for Becton Dickinson. The recent weakness is not just a short blip, with a 90 day share price return of 20.4% and an 18.3% year to date share price decline feeding into a 1 year total shareholder return of 8.2% and softer multi year...

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
StockStory
Mar 13, 2026

3 Healthcare Stocks Walking a Fine Line

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 3.8% return has closely followed the S&P 500.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 12, 2026

Becton, Dickinson Recieves FDA Clearance for Surgiphor 1000 ml Irrigation System

Becton, Dickinson and Company (NYSE:BDX) is included among the 13 Undervalued Dividend Aristocrats to Buy Now. Becton, Dickinson and Company (NYSE:BDX) is one of the world’s largest pure-play medical technology companies in the world. BD drives innovation across medical essentials, connected care, biopharma systems, and interventional. Becton, Dickinson and Company (NYSE:BDX) announced on March 2 […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 11, 2026

Why Is Becton Dickinson (BDX) Down 4.5% Since Last Earnings Report?

Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.